In summary, our data reveal a previously unrecognized oncogenic axis in GC, as PKA-dependent phosphorylation of SFRP4 switches it from a Wnt antagonist to a potent agonist, thereby driving stemness and chemoresistance. This evidence concerns the gene SFRP4 and gastric cancer.